Meeting
2023 ASCO Quality Care Symposium
Myelosuppression and healthcare utilization among patients with chemotherapy-treated extensive-stage small cell lung cancer (ES-SCLC) with and without trilaciclib from community oncology practices.
Authors
Ajeet Gajra
Hematology Oncology Associates of CNY, East Syracuse, NY
Ajeet Gajra, Peter Reeves, Susan O'Brien, Victor Giancarlo Sal y Rosas Celi, Michelle Moore, Huan Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 527)
DOI
10.1200/OP.2023.19.11_suppl.527
Abstract #
527
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.
First Author: Jerome H. Goldschmidt
Poster
2022 ASCO Annual Meeting
Impact of trilaciclib on multilineage chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer: Post-hoc analyses of data from randomized clinical trials.
First Author: Jerome H. Goldschmidt
Poster
2023 ASCO Quality Care Symposium
Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology.
First Author: L. Johnetta Blakely
Poster
2023 ASCO Annual Meeting
Rates of emergency department visits and acute-care hospital admissions after starting chemotherapy or having surgery across six community-based cancer centers.
First Author: Michael J. Hassett